首页> 外文期刊>Clinical Chemistry >Different Apparent Prognostic Value of hsCRP in Type 2 Diabetic and Nondiabetic Patients with Acute Coronary Syndromes
【24h】

Different Apparent Prognostic Value of hsCRP in Type 2 Diabetic and Nondiabetic Patients with Acute Coronary Syndromes

机译:hsCRP在2型糖尿病和非糖尿病急性冠脉综合征患者中的不同预后价值

获取原文
获取原文并翻译 | 示例
           

摘要

C-reactive protein (CRP) is an established prognostic marker in acute coronary syndromes (ACS); however, no study has specifically addressed its prognostic role in type 2 diabetes with ACS. We evaluated the prognostic role of CRP separately in diabetic and nondiabetic patients with ACS. We enrolled 251 patients with unstable angina and measured serum concentrations of high sensitivity (hs)CRP. Ninety-seven patients underwent coronary angiography with evaluation of atherosclerotic disease severity and extent by Bogaty score. Assessed endpoint was the combined occurrence of myocardial infarction (MI) and death at 1 year. No significant differences were found in hsCRP between patients with and without diabetes. By Cox regression, hsCRP was not associated with 1-year follow-up events in diabetic patients but was strongly associated with events in nondiabetic patients (P = 0.0012). Coronary angiography exhibited a higher extent index in patients with diabetes than in those without (P = 0.04). hsCRP concentrations were not associated with angiographic atherosclerotic burden. By Cox analysis, hsCRP and extent score were associated with events in patients who underwent coronary angiography (P < 0.001 and P = 0.034, respectively). In nondiabetic patients, hsCRP was the only predictor of events at 1-year follow-up (P < 0.001), whereas in diabetic patients, hsCRP was not associated with events and a weak association was observed for extent score (P = 0.06). Our study suggests that different pathophysiological mechanisms may be responsible for MI and death in unstable angina patients with or without diabetes and that severity of coronary artery disease plays a major role in diabetes (and inflammation in the absence of diabetes).
机译:C反应蛋白(CRP)是急性冠状动脉综合征(ACS)的既定预后标志物;但是,尚无任何研究明确探讨其在ACS中对2型糖尿病的预后作用。我们分别评估了CRP在糖尿病和非糖尿病ACS患者中的预后作用。我们招募了251位不稳定型心绞痛患者,并测量了高敏感性(hs)CRP的血清浓度。九十七例患者接受了冠状动脉造影,并通过Bogaty评分评估了动脉粥样硬化疾病的严重程度和程度。评估的终点是1年时心肌梗死(MI)和死亡的合并发生。在有和没有糖尿病的患者之间,hsCRP没有发现显着差异。通过Cox回归,hsCRP与糖尿病患者的1年随访事件无关,但与非糖尿病患者的事件密切相关(P = 0.0012)。与没有糖尿病的患者相比,冠状动脉造影显示的糖尿病患者范围指数更高(P = 0.04)。 hsCRP浓度与血管造影动脉粥样硬化负担无关。通过Cox分析,hsCRP和程度评分与接受冠状动脉造影的患者的事件相关(分别为P <0.001和P = 0.034)。在非糖尿病患者中,hsCRP是1年随访时事件的唯一预测因子​​(P <0.001),而在糖尿病患者中,hsCRP与事件无关,程度评分之间的关​​联性较弱(P = 0.06)。我们的研究表明,不同的病理生理机制可能导致不稳定型心绞痛患者(无论是否患有糖尿病)的心梗和死亡,并且冠状动脉疾病的严重程度在糖尿病(以及没有糖尿病的炎症)中起主要作用。

著录项

  • 来源
    《Clinical Chemistry》 |2009年第2期|p.365-368|共4页
  • 作者单位

    Luigi M. Biasucci,1* Giovanna Liuzzo,1 Roberta Della Bona,1 Milena Leo,1 Gina Biasillo,1 Dominick J. Angiolillo, 2 Antonio Abbate,3 Vittoria Rizzello,1 Giampaolo Niccoli,1 Simona Giubilato,1 and Filippo Crea11 Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy, 2 Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, 3 Virginia Commonwealth University Pauley Heart Center, Richmond, VA, * address correspondence to this author at: Cardiology Department, Catholic University, Largo A. Gemelli 8, 00168 Rome, Italy. E-mail lmbiasucci@virgilio.it.Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data, (b) drafting or revising the article for intellectual content, and (c) final approval of the published article.Authors' Disclosures of Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:Employment or Leadership: None declared.Consultant or Advisory Role: L.M. Biasucci, sanofi-aventis, Siemens Healthcare Diagnostics, Pfizer, and Roche Diagnostics.Stock Ownership: None declared.Honoraria: L.M. Biasucci, sanofi-aventis, Siemens Healthcare Diagnostics, and Merck Sharp & Dohme.Research Funding: This study was supported by research grant 7021546 by Catholic University of Rome.Expert Testimony: None declared.Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.,;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号